{
  "ticker": "AVE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974234",
  "id": "02974234",
  "pages": 8,
  "price_sensitive": true,
  "date": "20250730",
  "time": "0844",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250730/pdf/06m96yc740vr3k.pdf",
  "summary": "### **Avecho Biotechnology Limited \u2013 Quarterly Report (Appendix 4C) \u2013 Material Summary**  \n\n#### **Key Highlights (Operational/Financial)**  \n- **Phase III insomnia trial progress**: 131 participants enrolled (target: 210), interim readout expected early 2026.  \n- **Expansion**: Three new clinical sites opened (Sydney, Gold Coast), accelerating recruitment.  \n- **Licensing/commercialization**: Strategic planning with Sandoz for TGA registration; first-mover potential for OTC CBD insomnia product in Australia (market estimated >US$125m annually).  \n- **Cash balance**: **A$5.9m** (30 June 2025).  \n- **R&D Tax Incentive**: **A$1.66m** received (FY2024), used to repay A$1.04m in advances and fund trials.  \n\n#### **Appendix 4C (Cash Flow)**  \n- **Net operating cash outflow**: **A$0.68m** (quarter), **A$3.6m** positive YTD (boosted by R&D tax receipt).  \n- **Cash runway**: ~8.7 quarters (based on current burn).  \n\n#### **Material Catalysts**  \n- **Interim trial results (early 2026)** \u2013 pivotal for valuation and partnership prospects.  \n\n*Omitted: Routine corporate details, forward-looking disclaimers, non-material site specifics.*",
  "usage": {
    "prompt_tokens": 4787,
    "completion_tokens": 296,
    "total_tokens": 5083,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T22:57:04.544833"
}